Spero Therapeutics, Inc. Increase (Decrease) in Other Deferred Liability
Spero Therapeutics, Inc. (SPRO) reported Increase (Decrease) in Other Deferred Liability of $554.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherDeferredLiability · last filed 2020-03-16
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for the quarter ending 2018-12-31 was $645.00K.
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for the quarter ending 2018-09-30 was -$32.00K.
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for the quarter ending 2018-06-30 was -$23.00K, a 105.29% decline year-over-year.
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for the quarter ending 2018-03-31 was -$36.00K.
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for fiscal 2018 was $554.00K.
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for fiscal 2017 was -$128.00K.
- Spero Therapeutics, Inc. increase (decrease) in other deferred liability for fiscal 2016 was -$84.00K.
| Period end | Increase (Decrease) in Other Deferred Liability 3 month | Increase (Decrease) in Other Deferred Liability 6 month | Increase (Decrease) in Other Deferred Liability 9 month | Increase (Decrease) in Other Deferred Liability 12 month |
|---|---|---|---|---|
| 2018-12-31 | $645.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $613.00K derived: sum of 2 quarters · filed 2020-03-16 | $590.00K derived: sum of 3 quarters · filed 2020-03-16 | $554.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | -$32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$55.00K derived: sum of 2 quarters · filed 2019-11-04 | -$91.00K 10-Q · filed 2019-11-04 | -$124.00K derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$59.00K 10-Q · filed 2019-08-08 | -$92.00K derived: sum of 3 quarters · filed 2019-08-08 | -$125.00K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$36.00K 10-Q · filed 2019-05-09 | -$69.00K derived: sum of 2 quarters · filed 2019-05-09 | -$102.00K derived: sum of 3 quarters · filed 2019-05-09 | $333.00K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$66.00K derived: sum of 2 quarters · filed 2019-03-14 | $369.00K derived: sum of 3 quarters · filed 2019-03-14 | -$128.00K 10-K · filed 2019-03-14 |
| 2017-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $402.00K derived: sum of 2 quarters · filed 2018-11-08 | -$95.00K 10-Q · filed 2018-11-08 | -$123.00K derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$62.00K 10-Q · filed 2018-08-09 | -$90.00K derived: sum of 3 quarters · filed 2019-03-14 | |
| 2017-03-31 | -$497.00K 10-Q · filed 2018-05-10 | -$525.00K derived: sum of 2 quarters · filed 2019-03-14 | ||
| 2016-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$84.00K 10-K · filed 2019-03-14 | ||
| 2016-09-30 | -$56.00K 10-Q · filed 2017-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |